Post-authorisation Safety Study of Rimegepant in Patients with Migraine and History of Cardiovascular Disease in European Countries

First published 24/03/2023

Last updated 08/10/2025

EU PAS number:

EUPAS103990

Study

Planned

Documents

Study protocol

Initial protocol

C4951017_bhv3000-408 protocol v2_17 Nov 2022

English (1.29 MB - PDF) View document

Updated protocol

C4951017_PROTOCOL- RIMEGEPANT CV PASS_V3.0_26AUG2024.pdf

First published: 31/01/2025

English (2.29 MB - PDF) View document

Study results

Study report

C4951017_PROGRESS REPORT 1_V1.0_09Oct2024.pdf

English (169.57 KB - PDF) View document

Other information

Secondary tabs